The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.
Participants
- Sinead Delany-Moretlwe, MBBCh, Ph.D., DTM&H
HPTN 084 Protocol Chair
Wits Reproductive Health and HIV Insitute,
University of the Witswatersrand
- Mina Hosseinipour, MD, MPH
HPTN 084 Protocol Co-Chair
University of North Carolina at Chapel Hill School of Medicine,
UNC Project-Malawi